Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 USD | -2.91% | -10.71% | -54.55% |
02-22 | Baudax Bio, Inc. Filed for Bankruptcy | CI |
2023 | Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Sales 2021 | 1.08 86.11 | Sales 2022 | 1.27 101.18 | Capitalization | 1.76M 141M |
---|---|---|---|---|---|
Net income 2021 | -19M -1.51B | Net income 2022 | -58M -4.62B | EV / Sales 2021 | 17,166,252 x |
Net cash position 2021 | 6.35 506.6 | Net Debt 2022 | 2.68 213.35 | EV / Sales 2022 | 1,390,484 x |
P/E ratio 2021 |
-0.76
x | P/E ratio 2022 |
-0.02
x | Employees | 9 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.98% |
Latest transcript on Baudax Bio, Inc.
1 day | -2.91% | ||
1 week | -10.71% | ||
Current month | -23.08% | ||
1 month | -23.08% | ||
3 months | -61.39% | ||
6 months | -93.55% | ||
Current year | -54.55% |
Managers | Title | Age | Since |
---|---|---|---|
Gerri Henwood
CEO | Chief Executive Officer | 71 | 31/12/18 |
Natalie McAndrew
DFI | Director of Finance/CFO | 50 | 08/10/23 |
Diane Myers
PRN | Corporate Officer/Principal | 60 | 31/10/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 83 | 20/11/19 | |
Gerri Henwood
CEO | Chief Executive Officer | 71 | 31/12/18 |
Wayne Weisman
CHM | Chairman | 68 | 20/11/19 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 0.01 | -2.91% | 88,524 |
26/04/24 | 0.0103 | -8.04% | 14,336 |
25/04/24 | 0.0112 | +6.67% | 7,116 |
24/04/24 | 0.0105 | -0.94% | 6,065 |
23/04/24 | 0.0106 | -5.36% | 5,960 |
Delayed Quote OTC Markets, April 29, 2024 at 06:24 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-54.55% | 540K | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- BXRXQ Stock